CIK 0001563880 · Non-accelerated filer<br>Smaller reporting company
Trevi Therapeutics, Inc.
Sign in to watch- Ticker
- TRVI
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 450834299
- Phone
- 203-304-2499
- Business address
- 195 CHURCH STREET, 16TH FLOOR, NEW HAVEN, CT, 06510
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $595,806
- in 1 filing, $596K under 10b5-1 plans
Net −$595,806. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-10 | Galletta Christopher See Remarks | Grant or award · Performance Stock Option (right to buy) | +4,560 | 4,560 | ||
| 2025-03-10 | Simon Farrell Chief Commercial Officer | Option exercise 10b5-1 | +17,500 | $3.21 | $56K | 63,150 |
| 2025-03-10 | Simon Farrell Chief Commercial Officer | Option exercise 10b5-1 | +63,813 | $3.91 | $250K | 126,963 |
| 2025-03-10 | Simon Farrell Chief Commercial Officer | Option exercise 10b5-1 | +31,250 | $0.51 | $16K | 158,213 |
| 2025-03-10 | Simon Farrell Chief Commercial Officer | Sale 10b5-1 | −76,963 | $6.73 | $518K | 81,250 |
| 2025-03-10 | Simon Farrell Chief Commercial Officer | Sale 10b5-1 | −4,350 | $7.15 | $31K | 76,900 |
| 2025-03-10 | Simon Farrell Chief Commercial Officer | Grant or award · Performance Stock Option (right to buy) 10b5-1 | +38,400 | 38,400 | ||
| 2025-03-10 | Simon Farrell Chief Commercial Officer | Option exercise · Performance Stock Option (right to buy) 10b5-1 | −17,500 | 0 | ||
| 2025-03-10 | Simon Farrell Chief Commercial Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −63,813 | 11,187 | ||
| 2025-03-10 | Simon Farrell Chief Commercial Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −31,250 | 18,750 | ||
| 2025-02-18 | SCIASCIA THOMAS Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +116,000 | 116,000 | ||
| 2025-02-18 | Cassella James V Chief Development Officer | Grant or award · Stock Option (right to buy) | +257,500 | 257,500 | ||
| 2025-02-18 | Simon Farrell Chief Commercial Officer | Grant or award · Stock Option (right to buy) | +225,500 | 225,500 | ||
| 2025-02-18 | Delfini Lisa Chief Financial Officer | Grant or award · Stock Option (right to buy) | +225,500 | 225,500 | ||
| 2025-02-18 | GOOD JENNIFER L President & CEO | Grant or award · Stock Option (right to buy) | +811,000 | 811,000 | ||
| 2025-02-18 | Galletta Christopher See Remarks | Grant or award · Stock Option (right to buy) | +41,000 | 41,000 | ||
| 2025-01-08 | Delfini Lisa Chief Financial Officer | Option exercise | +5,000 | $0.51 | $3K | 64,660 |
| 2025-01-08 | Delfini Lisa Chief Financial Officer | Option exercise · Stock Option (right to buy) | −5,000 | 42,125 | ||
| 2025-01-07 | Delfini Lisa Chief Financial Officer | Option exercise | +1,000 | $0.51 | $511 | 59,660 |
| 2025-01-07 | Delfini Lisa Chief Financial Officer | Option exercise · Stock Option (right to buy) | −1,000 | 47,125 |
Page 3 of 9 · 179 trades